Detail akcie Quantum Rev.split online

Business Summary: Quantum Genomics SA is a France-based company. The Company is a biopharmaceutical company dedicated to developing new therapies for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure. Its main activity is in research and development of new therapies for the treatment of hypertension, BAPAI (Brain Aminopeptidase A Inhibitors) oriented in the field of cardiovascular diseases, especially high blood pressure and heart failure. The Company also co-develops products with academic teams, biotechnological research entities, and some of the pharmaceutical and bio-science companies. The Company is involved in four research programs. Quantum Genomics also collaborates with Center for Clinical Investigation 9201 APHP / INSERM of the Georges Pompidou European Hospital in Paris, among others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Quantum Genomics SA revenues decreased from EUR10K to EUR0K. Net loss increased from EUR3.2M to EUR8.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Increase of Provisions and Amort/Depr increase from EUR382K to EUR7.4M (expense), Other Non Rec I/E - Non Business Act decrease of 88% to EUR30K (income).